Natus Medical Price Target Increased to $22.00 by Analysts at Roth Capital (BABY)
Stock analysts at Roth Capital hoisted their target price on shares of Natus Medical (NASDAQ:BABY) from $15.00 to $22.00 in a report issued on Friday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Roth Capital’s price objective would indicate a potential upside of 12.70% from the stock’s previous close.
Separately, analysts at Zacks upgraded shares of Natus Medical from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, October 1st. They now have a $15.40 price target on the stock.
Shares of Natus Medical (NASDAQ:BABY) opened at 19.52 on Friday. Natus Medical has a 52 week low of $9.65 and a 52 week high of $15.18. The stock’s 50-day moving average is $13.48 and its 200-day moving average is $13.42. The company has a market cap of $584.7 million and a price-to-earnings ratio of 55.17.
Natus Medical (NASDAQ:BABY) last announced its earnings results on Thursday, October 24th. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.19 by $0.11. The company had revenue of $85.40 million for the quarter, compared to the consensus estimate of $80.83 million. During the same quarter last year, the company posted $0.15 earnings per share. Natus Medical’s revenue was up 5.4% compared to the same quarter last year. Analysts expect that Natus Medical will post $0.90 EPS for the current fiscal year.
Natus Medical Incorporated (NASDAQ:BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.